Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Biotechnology
Changsheng Biotechnology is the subject of an ongoing controversy this week, after an inspection in mid-July found the company had fabricated production and inspection documents related to the production of 250,000 faulty rabies vaccines. 23 July 2018
Pharmaceutical
Four years after its initial approval in moderate to severe Crohn’s disease, Japan’s Takeda Pharmaceutical has finally submitted Entyvio (vedolizumab) for approval in its home country. 18 July 2018
Pharmaceutical
The European Union and Japan have agreed to broaden the range of medicines for which they will recognize each other’s inspections of manufacturing sites. 18 July 2018
Pharmaceutical
Roche and Chugai Pharmaceutical have agreed a licensing deal whereby the latter will develop and market the tyrosine kinase inhibitor entrectinib in Japan. 18 July 2018
Pharmaceutical
Takeda Pharmaceutical chief executive Christophe Weber says his company will look to China for future growth in the wake of his firm’s mega-takeover of rare disease specialist Shire. 18 July 2018
Pharmaceutical
In what might be seen as a benefit of one-party rule, while US President Donald Trump grapples with his apparent powerlessness to reign in drug prices, the Chinese state seems determined to unilaterally reduce costs for cancer meds. 10 July 2018
Pharmaceutical
Amazon's acquisition of PillPack will be troubling to big pharma executives throughout the industry, with the company having such vast existing revenue streams that it could outspend many of the sector's existing inhabitants. 10 July 2018
Generics
The European Medicines Agency (EMA) is reviewing medicines containing the active substance valsartan that is supplied by Zhejiang Huahai Pharmaceuticals, a company based in Linhai, China. 6 July 2018
Pharmaceutical
Osaka’s Sumitomo Dainippon Pharma has submitted a new drug application in Japan for its candidate DSP-1958 (thiotepa), as a conditioning treatment prior to autologous hematopoietic stem cell transplantation (HSCT) for pediatric solid tumors. 5 July 2018
Biotechnology
East Coast, USA-based firm Athenexhas announced several key strategic deals focused on China, aimed at furthering its oncology developments. 3 July 2018
Pharmaceutical
Japan’s Sumitomo Dainippon Pharma has received approval in its home country for Trerief (zonisamide) as a treatment for parkinsonism in dementia with Lewy bodies (DLB). 3 July 2018
Pharmaceutical
There was good news for Anglo-Swedish pharma major AstraZeneca and its partners, with fast-track approval from Japan’s regulator for their breast cancer and lung cancer drugs. 2 July 2018
Biotechnology
I-Mab Biopharma, a Chinese biotech company focusing on innovative biologics in therapeutic areas of immuno-oncology and immuno-inflammation, has completed a Series C financing for $220 million, representing one of the largest amounts ever raised in Series C by an innovative biotech company in China. 2 July 2018
Biotechnology
The Japanese medicines regulator has approved Tokyo-based Takeda Pharmaceutical’s application to market Entyvio (vedolizumab) in ulcerative colitis (UC). 2 July 2018
Pharmaceutical
Earlier this month, Jiao Hong, Commissioner of the National Drug Administration of China (CNDA), met with the visiting deputy Secretary General of the United Nations and the executive director of the UNAIDS Program, Michel Sidibe, and his party. 25 June 2018
Biotechnology
Independent mitochondrial DNA specialist Stealth BioTherapeutics has raised $100 million from Nan Fung Technology’s Pivotal Beta and other new and existing investors. 20 June 2018
Pharmaceutical
Following a deal late last year that gave Bayer access to valuable customer data, Chinese e-commerce platform Alibaba has entered into another collaboration with a German pharma major, this time Darmstadt’s Merck,. 20 June 2018
Biotechnology
Bristol-Myers Squibb has announced that the Chinese National Drug Administration (CNDA) has approved Opdivo (nivolumab) for lung cancer patients, the first immuno-oncology therapy ever to be approved in the country. 15 June 2018
Pharmaceutical
A ruling in the Supreme Court of the United States (SCOTUS) on Thursday found that foreign law deserves ‘respectful consideration’ but should not determine a class action’s outcome. 15 June 2018
Biotechnology
US clinical-stage biotech Sage Therapeutics has entered into a strategic collaboration for the clinical development and commercialization of SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea. 14 June 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze